Drug Studies for Patients in the filed of internal medicine/infectiology in Berlin

There is a long way to go until a new drug is ready to be sold in pharmacies. It takes as long as ten years from the first development of a potential remedy to the final approval by the authorities.

 As a matter of fact, EPIMED has been involved in the testing of many of today’s indispensable and well-tolerated  drugs and EPIMED Patients have often the opportunity to be treated with highly effective substances not yet available on the market.

What is a Clinical Study?

The steps of the development of a drug are divided in the pre-clinical (Laboratory, “in vitro”, animal experiments) and in clinical studies.

In the phase I(a) studies a substance will be applied for the first time in humans. These studies are conducted with healthy test persons without the relevant medical condition the drug is developed for to assess the tolerability, the metabolism and the toxicity of a substance. At EPIMED, we do not carry out this phase of trials, yet we do participate in phase I(b) studies. In these clinical trials a drug in development will be studied for the first time in patients bearing the relevant medical condition the drug is being developed for.

Phase II and III studies are research and therapy studies with patients. They are needed to investigate the efficacy, dose finding, development of the pharmaceutical formula, establishing of the side effect profile and the long time tolerability.

Phase IV studies are carried out after the final approval of a drug, e.g. an analysis concerning the long term side effects.

Who Conducts Clinical Studies?

The sponsors are mostly pharmaceutical companies but also national or independent research institutes. Studies are carried out in hospitals and, to a lesser extent, in private practices.

EPIMED is a joint venture of twelve specialists’ practices in the field of internal medicine/infectiology and the Department of Internal Medicine /Infectious diseases of the Vivantes Auguste-Viktoria-Klinikum. We offer drug studies for patients since 1997.

Will I Become a Guinea-Pig if I Take Part in a Study?

We would not need clinical studies with humans, if only we knew all pros and cons, the efficacy and lack of efficacy of new substances readily at the beginning. Yet this does not make a study participant to a guinea-pig. The most important difference is the complete voluntariness of the participation and the opportunity to withdraw from the study at any point. For this reason studies are not allowed in correctional facilities and the concern of the patient safety of physical integrity is always paramount to the scientific advance and the marketing effort of the pharmaceutical companies.

The patient safety is regulated by German constitutional law and the Declaration of Helsinki of the World Medical Association, the German law on pharmaceutical products (Arzneimittelgesetz) as well as European and international regulations (ICH-GCP). The crucial point is a thorough informed consent with explanation of the advantages and potential risks of the study that will be signed by the patient and the trial physician, as well as insurance for the test persons with high coverage. Before a study can start it has to be approved by an ethics committee. In Berlin it is the ethics committee of the health authorities (Landesamt für Gesundheit und Soziales)


Which Advantages Do I Have if I participate in a Clinical Study?

Your benefits can be both, good for your health and good for cost saving. Drugs will be provided by the sponsor and medical examination and treatment is free within the context of the clinical study. In terms of health you may profit a multiple. On the one hand an early treatment with new substances could be presumably more effective, could possibly cause less side effects or the substances are simply more convenient to take. On the other hand you will be examined with the most up-to-date techniques and frequent laboratory analyses, which both will endorse your specialist’s / GPs medical care.

What Will Be Done in the Course of a Clinical Trial?

Your treating physician will check whether your data in the patient record and your actual laboratory results fit into the inclusions and exclusions criteria of the study protocol. The eligibility will be finally checked at the screening visit in the EPIMED central unit in Vivantes Auguste-Viktoria-Klinikum. Many studies have to be placebo controlled and double blind for the scientific scrutiny of the outcome. Therefore, you will be randomized to one of the treatment arms with either the active substance or placebo at the baseline visit. Such studies have a short duration to avoid any harm to the participants. Other studies may last up to several years. The sponsor offers adequate reimbursement for mere research studies with no treatment aspect that involve blood tests of the drug concentration (pharmacokinetics) and a longer stay in the study centre from 8 up to 48 hours. Other studies may include reimbursement of travel expenses.

What Makes EPIMED so Special in Comparison with other Trial Sites?

We put a strong emphasis on the cooperation between the treating physician and the trial physician, between the research and the everyday medical treatment as well as between the hospital and the specialists’ practices. This means that your treating physician receives the study results and the concomitant medication is directly addressed with the treating physician Peripheral Investigators. At EPIMED you are taken care by a team of experienced and competent physicians, study coordinators and study assistants.

Last change: 21-JAN-2020